Introduction And Hypothesis: Previous studies have found that administration of phenazopyridine decreased short-term urinary retention following surgery but other more recent trials have shown mixed results. This study sought to investigate the potential benefit of preoperative administration of oral phenazopyridine in relation to the prevention of short-term urinary retention following urogynecologic surgery.
Methods: This is a retrospective cohort study of a convenience sample of women undergoing urogynecologic surgery from June 2016 to March 2019. Following surgery, subjects underwent a standardized retrograde voiding trial. The data had previously been gathered from a prior prospective trial at our institution (Kesty et al. Int Urogynecol J 31(9):1899-1905, 11). Chart review was performed to determine whether patients that received 200 mg of preoperative oral phenazopyridine to better visualize ureteral efflux during cystourethroscopy were more or less likely to pass their postoperative voiding trial. Bivariate statistical analysis was performed as well as a multivariate logistic regression model.
Results: A total of 165 subjects were included in the final analysis; 100 who did not receive preoperative phenazopyridine and 65 who did receive phenazopyridine. There was no statistical difference between voiding trial pass rates following urogynecologic surgery between those who did not receive preoperative phenazopyridine compared to those who did [77% (77/100) and 82% (53/65), respectively, p = 0.37)]. The multivariate logistic regression model demonstrated no difference in postoperative voiding trial pass rates among those who received preoperative phenazopyridine compared to those who did not (OR 1.7, 95% CI: 0.53, 5.8).
Conclusions: Preoperative administration of oral phenazopyridine does not decrease short-term urinary retention following urogynecologic surgery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00192-021-04699-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cost Analysis of Oral Phenazopyridine vs Intravesical Lidocaine for Preprocedural Analgesia for Intradetrusor OnabotulinumtoxinA Injections.
Urol Pract
September 2024
Departments of Obstetrics and Gynecology and Urology, NYU Langone Health, New York, New York.
Introduction: Office administration of intradetrusor onabotulinumtoxinA is commonly used to treat overactive bladder. For preprocedure analgesia, either 50 mL 2% intravesical lidocaine instillation for 20 to 30 minutes or 200 mg oral phenazopyridine can be used. Phenazopyridine is associated with shorter appointment times and is noninferior to lidocaine for pain control in this setting.
View Article and Find Full Text PDFRepair of Vesicovaginal Fistulae: A Systematic Review.
Obstet Gynecol
February 2024
Northwest Kaiser Permanente, Portland, Oregon; the University of Texas Medical Branch, Galveston, the University of Texas at San Antonio, San Antonio, UT Southwestern Medical Center, Dallas, and the Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, Texas; the Woman's Center for Advanced Pelvic Surgery, Phoenix, Arizona; MedStar Washington Hospital Center, Washington, DC; the Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada; Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; the International Medical Response Foundation, Brooklyn, New York; the Center for Evidence Synthesis in Health, Brown University School of Public Health, Providence, Rhode Island; Cooper Medical School of Rowan University, Cooper University Health Care, Camden, New Jersey; and the Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque, New Mexico.
Objective: To assess and compile the current level of evidence regarding successful surgical treatment of vesicovaginal fistulae and how these perioperative interventions affect anatomic, patient-centered, and adverse outcomes.
Data Sources: PubMed and EMBASE were searched from inception through September 9, 2022.
Methods Of Study Selection: This review included comparative studies (of any sample size) and single-group studies (1,000 or more participants) of primary or recurrent vesicovaginal fistula (ie, vesicovaginal fistula, urethrovaginal fistula, and bladder neck-vaginal fistula).
Commentary: The effect of preoperative phenazopyridine on short-term urinary retention following urogynecologic surgery.
Int Urogynecol J
June 2021
Department of Urology, Cedas Sinai Medical Center, Los Angeles, CA, USA.
The effect of preoperative phenazopyridine on short-term urinary retention following urogynecologic surgery.
Int Urogynecol J
March 2022
Department of Obstetrics and Gynecology, Medical University of South Carolina, 96 Jonathan Lucas Street MSC 619, Charleston, SC, 29425, USA.
Introduction And Hypothesis: Previous studies have found that administration of phenazopyridine decreased short-term urinary retention following surgery but other more recent trials have shown mixed results. This study sought to investigate the potential benefit of preoperative administration of oral phenazopyridine in relation to the prevention of short-term urinary retention following urogynecologic surgery.
Methods: This is a retrospective cohort study of a convenience sample of women undergoing urogynecologic surgery from June 2016 to March 2019.
The Effect of Phenazopyridine on Immediate Postoperative Voiding After Prolapse Surgery: A Randomized Controlled Trial.
Female Pelvic Med Reconstr Surg
February 2021
From the Division of Urogynecology and Reconstructive Pelvic Surgery, University of Massachusetts Medical School, Worcester, MA.
Objectives: The objective of our study was to determine if phenazopyridine reduces void trial (VT) failure rates after prolapse surgery.
Methods: A single-institution randomized controlled trial was conducted comparing a second dose of phenazopyridine 200 mg on postoperative day 1 versus no additional phenazopyridine in women undergoing prolapse surgery. All subjects (including controls) received 200 mg of phenazopyridine preoperatively for ureteral patency verification.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!